Skip to main content
. 2024 Jun 20;16(6):e62775. doi: 10.7759/cureus.62775

Figure 7. Average values obtained for the environmental well-being domain for the two groups.

Figure 7

Group HF-S/V, patients undergoing treatment with sacubitril/valsartan; Group HF-CT, patients receiving conventional therapy